News >

FDA Grants Priority Review to Capmatinib in METex14+ NSCLC

Jason M. Broderick
Published: Tuesday, Feb 11, 2020

The FDA has granted a priority review designation to a new drug application (NDA) for capmatinib (INC280) for use as treatment for newly diagnosed and previously treated patients with locally advanced or metastatic MET exon14 skipping (METex14)—mutated non–small cell lung cancer (NSCLC).1

ex14—mutated non–small cell lung cancer.


  1. Novartis announces MET inhibitor capmatinib (INC280), the first potential treatment for METex14 mutated advanced non-small cell lung cancer, granted priority FDA review. Published February 11, 2020. Accessed February 11, 2020.           
  2. Wolf J, Setons T, Han J-Y, et al. Capmatinib (INC280) in METΔex14-mutated advanced non-small cell lung cancer (NSCLC): efficacy data from the phase II GEOMETRY mono-1 study. J Clin Oncol. 2019;37(suppl; abstr 9004). doi: 10.1200/JCO.2019.37.15_suppl.9004.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication